Kazia Therapeutics (KZIA) Revenue & Revenue Breakdown
Kazia Therapeutics Revenue Highlights
Latest Revenue (Y)
$555.00
Latest Revenue (Q)
$5.00
Main Segment (Y)
Licensing Revenue
Main Geography (Y)
CHINA
Kazia Therapeutics Revenue by Period
Kazia Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-06-30 | $555.00 | 2120.00% |
| 2022-06-30 | $25.00 | -100.00% |
| 2021-06-30 | $15.18M | 1430881.24% |
| 2020-06-30 | $1.06K | -32.20% |
| 2019-06-30 | $1.56K | -88.06% |
| 2018-06-30 | $13.11K | -99.85% |
| 2017-06-30 | $8.79M | 115.87% |
| 2016-06-30 | $4.07M | 4474.16% |
| 2015-06-30 | $89.00K | 2.30% |
| 2014-06-30 | $87.00K | -91.85% |
| 2013-06-30 | $1.07M | -56.44% |
| 2012-06-30 | $2.45M | 20.99% |
| 2011-06-30 | $2.02M | -79.56% |
| 2010-06-30 | $9.91M | -11.12% |
| 2009-06-30 | $11.15M | -16.03% |
| 2008-06-30 | $13.28M | -23.33% |
| 2007-06-30 | $17.31M | 28.21% |
| 2006-06-30 | $13.50M | -23.30% |
| 2005-06-30 | $17.61M | 7.71% |
| 2004-06-30 | $16.35M | -50.36% |
| 2003-06-30 | $32.93M | 68.06% |
| 2002-06-30 | $19.59M | -66.74% |
| 2001-06-30 | $58.91M | 120.27% |
| 2000-06-30 | $26.75M | 38.41% |
| 1999-06-30 | $19.32M | - |
Kazia Therapeutics generated $555.00 in revenue during NA 2023, up 2120.00% compared to the previous quarter, and up 4.23% compared to the same period a year ago.
Kazia Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $5.00 | -99.10% |
| 2023-06-30 | $555.00 | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $-2.90M | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $10.00K | 100.00% |
| 2021-09-30 | $5.00K | -99.97% |
| 2021-06-30 | $15.18M | 1297467.61% |
| 2020-12-31 | $1.17K | -99.68% |
| 2020-06-30 | $362.43K | 100.00% |
| 2020-03-31 | $181.21K | -71.04% |
| 2019-12-31 | $625.68K | 100.00% |
| 2019-09-30 | $312.84K | -53.43% |
| 2019-06-30 | $671.76K | 100.00% |
| 2019-03-31 | $335.88K | -56.28% |
| 2018-12-31 | $768.24K | 100.00% |
| 2018-09-30 | $384.12K | -75.30% |
| 2018-06-30 | $1.55M | 100.00% |
| 2018-03-31 | $777.45K | -46.36% |
| 2017-12-31 | $1.45M | 100.00% |
| 2017-09-30 | $724.65K | -82.75% |
| 2017-06-30 | $4.20M | -8.39% |
| 2016-12-31 | $4.59M | 1842.73% |
| 2016-06-30 | $236.09K | 100.00% |
| 2016-03-31 | $118.04K | -96.11% |
| 2015-12-31 | $3.04M | 100.00% |
| 2015-09-30 | $1.52M | 1075.31% |
| 2015-06-30 | $129.15K | 100.00% |
| 2015-03-31 | $64.57K | -95.94% |
| 2014-12-31 | $1.59M | -45.16% |
| 2008-06-30 | $2.90M | -18.15% |
| 2008-03-31 | $3.54M | 3.68% |
| 2007-12-31 | $3.41M | -0.05% |
| 2007-09-30 | $3.42M | 0.00% |
| 2007-06-30 | $3.42M | 0.35% |
| 2007-03-31 | $3.40M | -35.16% |
| 2006-12-31 | $5.25M | 0.25% |
| 2006-09-30 | $5.24M | 115.86% |
| 2006-06-30 | $2.43M | -0.27% |
| 2006-03-31 | $2.43M | -43.75% |
| 2005-12-31 | $4.33M | -0.02% |
| 2005-09-30 | $4.33M | -40.03% |
| 2005-06-30 | $7.21M | 137.55% |
| 2005-03-31 | $3.04M | -36.74% |
| 2004-12-31 | $4.80M | 0.10% |
| 2004-09-30 | $4.79M | 4.85% |
| 2004-06-30 | $4.57M | 11.69% |
| 2004-03-31 | $4.09M | -0.39% |
| 2003-12-31 | $4.11M | -0.04% |
| 2003-09-30 | $4.11M | -78.42% |
| 2003-06-30 | $19.05M | 288.00% |
| 2003-03-05 | $4.91M | 0.03% |
| 2002-12-31 | $4.91M | 0.01% |
| 2002-09-30 | $4.91M | 0.62% |
| 2002-06-30 | $4.88M | -0.53% |
| 2002-03-31 | $4.90M | 0.14% |
| 2001-12-31 | $4.90M | 0.02% |
| 2001-09-30 | $4.90M | -60.59% |
| 2001-06-30 | $12.42M | -19.83% |
| 2001-03-31 | $15.50M | 14.85% |
| 2000-12-31 | $13.49M | -2.53% |
| 2000-09-30 | $13.84M | -751.15% |
| 2000-06-30 | $-2.13M | -122.09% |
| 2000-03-31 | $9.62M | 7.59% |
| 1999-12-31 | $8.95M | -0.27% |
| 1999-09-30 | $8.97M | - |
Kazia Therapeutics generated $5.00 in revenue during Q2 2024, up -99.10% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Kazia Therapeutics Revenue Breakdown
Kazia Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Jun 21 |
|---|---|
| Licensing Revenue | $15.18M |
Kazia Therapeutics's latest annual revenue breakdown by segment (product or service), as of Jun 21: Licensing Revenue (100.00%).
Kazia Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Jun 21 |
|---|---|
| CHINA | $10.01M |
| Swedan | $5.18M |
Kazia Therapeutics's latest annual revenue breakdown by geography, as of Jun 21: CHINA (65.90%), and Swedan (34.10%).
Kazia Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| NRIX | Nurix Therapeutics | $76.99M | $12.09M |
| OCUL | Ocular Therapeutix | $58.44M | $14.71M |
| SEER | Seer | $16.66M | $3.07M |
| MREO | Mereo BioPharma Group | $10.00M | - |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| HCWB | HCW Biologics | $2.84M | $618.85K |
| QSI | Quantum-Si | $1.08M | $457.00K |
| MNOV | MediciNova | $1.00M | - |
| KZIA | Kazia Therapeutics | $555.00 | $5.00 |
| NLSP | NLS Pharmaceutics | - | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABIO | ARCA biopharma | - | - |
| RNXT | RenovoRx | - | - |
| OKYO | OKYO Pharma | - | - |
| ACHL | Achilles Therapeutics | - | - |
| CADL | Candel Therapeutics | - | - |
| SLS | SELLAS Life Sciences Group | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
| KTTA | Pasithea Therapeutics | - | - |
KZIA Revenue FAQ
What is Kazia Therapeutics’s yearly revenue?
Kazia Therapeutics's yearly revenue for 2023 was $555, representing an increase of 2120.00% compared to 2022. The company's yearly revenue for 2022 was $25, representing a decrease of -100.00% compared to 2021. KZIA's yearly revenue for 2021 was $15.18M, representing an increase of 1430881.24% compared to 2020.
What is Kazia Therapeutics’s quarterly revenue?
Kazia Therapeutics's quarterly revenue for Q2 2024 was $5, a -99.10% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q4 2022). The company's quarterly revenue for Q4 2023 was $555, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022). KZIA's quarterly revenue for Q2 2023 was $0, a 100.00% increase from the previous quarter (Q1 2023), and a -100.00% decrease year-over-year (Q2 2022).
What is Kazia Therapeutics’s revenue growth rate?
Kazia Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -64.54%.
What are Kazia Therapeutics’s revenue streams?
Kazia Therapeutics's revenue streams in n 21 are Licensing Revenue
What is Kazia Therapeutics’s main source of revenue?
For the fiscal year ending Jun 21, the largest source of revenue of Kazia Therapeutics was Licensing Revenue. This segment made a revenue of $15.18M, representing 100.00% of the company's total revenue.